healthcare

Should AbbVie Be More Concerned About Its California Case for Humira?

AbbVie Inc. (NYSE: ABBV) shares took a dip on Wednesday after it was announced that the pharmaceutical giant would be facing a lawsuit from the California Department of Insurance in ...
Read Full Story »

Clovis Finally Faces the Music for Fraudulent Lung Cancer Drug Results

Clovis Oncology Inc. (NASDAQ: CLVS) shares might not be showing it now, but the company is facing some heat from the U.S. Securities and Exchange Commission (SEC). The company, its ...
Read Full Story »

Pot Grower Tilray Still Zooming

Canada-based marijuana grower Tilray Inc. (NASDAQ: TLRY) added nearly 30% to its share price on Tuesday to close at $154.98, after posting a new post-IPO high of $155.10. In Wednesday's ...
Read Full Story »

Why Tilray Shares Are Getting Even Higher

Tilray Inc. (NASDAQ: TLRY) continued its incredible rally with shares up massively on Tuesday after the U.S. Drug Enforcement Administration granted approval for the company to import a cannabinoid study ...
Read Full Story »

Why Viking Therapeutics Fatty Liver Study More Than Doubled Shares

Viking Therapeutics Inc. (NASDAQ: VKTX) shares more than doubled on Tuesday after the company announced results from its midstage non-alcoholic fatty liver disease (NAFLD) trial. Specifically, Viking announced positive topline ...
Read Full Story »

CRISPR Therapeutics Partners Up to Take on Diabetes

CRISPR Therapeutics A.G. (NASDAQ: CRSP) shares dipped on Monday after the company announced a collaboration with ViaCyte focused on the discovery, development and commercialization of gene-edited allogeneic stem cell therapies ...
Read Full Story »

Urovant Closes in on IPO

Urovant Sciences has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company intends to price its 10 million ...
Read Full Story »

How Teva Won FDA Approval for Ajovy

Teva Pharmaceuticals Ltd. (NYSE: TEVA) shares made a solid gain early Monday after the company announced a critical approval by the U.S. Food and Drug Administration (FDA). Specifically, the FDA ...
Read Full Story »

Principia Biopharma Adds Even More Shares to IPO

Principia Biopharma has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company now intends to price its 6.25 ...
Read Full Story »

What This FDA Approval Means for STAAR Surgical

STAAR Surgical Co. (NASDAQ: STAA) shares made a handy gain on Friday after the firm announced a key approval by the U.S. Food and Drug Administration (FDA). The FDA granted ...
Read Full Story »

Allogene Therapeutics Files for IPO

Allogene Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) in regards to its initial public offering (IPO). No pricing details were given in the ...
Read Full Story »

Can Acorda Therapeutics Get Past This FDA Move?

Acorda Therapeutics Inc. (NASDAQ: ACOR) shares dipped on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) would be delaying its Prescription Drug User Fee Act ...
Read Full Story »

Why Progenics Shares Are Getting Crushed

Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) shares dropped sharply on Thursday after the company announced late-stage results from its prostate cancer study. Specifically, the firm announced top-line data from its Phase ...
Read Full Story »

Short Sellers Back Off Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Up the Ante in Major Biotechs

The short interest data are out for the most recent settlement date, August 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »